openPR Logo

Press Releases from Rosa and Co (34 total)

Dr. Arthur Lo, Theravance, to Discuss a Viral Kinetics Model for Optimizing Comp …

Dr. Lo will present the Webinar “Integration of in vitro data into a viral kinetics model to investigate rapid development of Hepatitis C resistance to therapy” on November 14, 2012. Rosa & Co. LLC today announced that Dr. Arthur Lo, Senior Scientist at Theravance, will present a webinar “Integration of in vitro data into a viral kinetics model to investigate rapid development of Hepatitis C resistance to therapy” on Wednesday, November

Dr. Toufigh Gordi to discuss the Selection of Appropriate Mathematical Modeling …

Dr. Gordi, will discuss choice of models and their Impact in the Drug Development Process on November 28, 2012 in Frankfort, Germany Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that Dr. Toufigh Gordi, President of PK/PD and Clinical Pharmacology Services, will present a talk at the 4th World PK/PD Summit on November 28, 2012, in Frankfort, Germany. The talk, entitled

Dr. Pratap Singh, to Discuss PK/PD Modeling Analysis of a Compound Targeting Mus …

Dr. Singh, will present “Role of Myostatin in Muscle Growth: Key Learnings From PK/PD Modeling Analysis” Webinar October 17, 2012. Rosa & Co. LLC today announced that Dr. Pratap Singh, Senior Principal Scientist at Pfizer, will present a webinar “Role of Myostatin in Muscle Growth: Key Learnings From PK/PD Modeling Analysis” on Wednesday, October 17, 2012 at 1:00 - 2:00 pm EDT as part of Rosa’s ongoing monthly public webinar series.

Dr. Malcolm Rowland, to Discuss Physiologically-Based Pharmacokinetics in Rosa …

Dr. Rowland, will present “Drug development and physiologically based pharmacokinetics” Webinar September 19, 2012 Rosa & Co. LLC today announced that Dr. Malcolm Rowland, Professor Emeritus, University of Manchester, will present a webinar “Addressing drug development questions with physiologically based pharmacokinetics” on Wednesday, September 19, 2012 at 12:00 - 1:00 pm EDT as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation

GlaxoSmithKline and Rosa Present Psoriasis Collaboration Results at 17th Interna …

PhysioPD™ modeling collaboration in psoriasis to be presented September 9-13, 2012. Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that results from its Psoriasis PhysioPD collaboration with Stiefel, a GSK Company, will be presented at the 17th International Inflammation Research Association Conference in Lake George, NY, September 9-13th, 2012. Dr. Betty Hussey, Director, Clinical Pharmacology of GSK will present a poster

Rosa to Present Mechanistic Systems Pharmacology Workshop at 2012 ICSB Conferenc …

Workshop focused on Rosa’s Model Qualification Method to be held August 19th, Toronto, Canada. Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present a mechanistic systems pharmacology workshop at ICSB-2012 - the 13th International Conference on Systems Biology in Toronto, Canada on August 19th, 2012. Dr. Christina Friedrich will be presenting the workshop entitled "Using Mechanistic Systems Pharmacology

Rosa to Present at 2012 PaSiPhIC Conference

Modeling analysis utilizes AMS/microdosing to improve drug development for infants. Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent research project will be presented at the 2012 3rd Annual Pacific Coast Statisticians and Pharmacometricians Innovation Conference in San Luis Obispo, CA on June 25, 2012. Dr. Toufigh Gordi will be presenting a poster entitled "Using PK

Dr. Scott Siler to Discuss DILIsym Model in Rosa’s World-Wide Webinar Series, …

Dr. Siler, will present “The DILIsym™ model and its application to hepatotoxicity testing in drug development” Webinar June 19, 2012 Rosa & Co. LLC today announced that Dr. Scott Siler, DILI-sim Consultant, will present a webinar “The DILIsym model and its application to hepatotoxicity testing in drug development” on Tuesday, June 19, 2012 at 1:00 - 2:00 pm EDT as part of Rosa’s ongoing monthly public webinar series. The purpose of

Rosa to Present Beta Cell Mass Research at 2012 ADA Annual Meeting

Modeling analysis enables development of clinical markers for beta cell mass. Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent research project will be presented at the 2012 American Diabetes Association Annual Meeting in Philadelphia, PA on June 10, 2012. Dr. Rebecca Baillie will be presenting a poster entitled "Non-invasive prediction of beta cell mass in

Dr. Toufigh Gordi to Discuss Pediatric PK Model in Rosa’s World-Wide Webinar S …

Dr. Gordi, will present “Mechanistic PK/PD Modeling in Pediatrics” Webinar May 22, 2012. Rosa & Co. LLC today announced that Dr. Toufigh Gordi, Rosa & Co, will present a webinar “Mechanistic PK/PD Modeling in Pediatrics” on Tuesday, May 22, 2012 at 1:00 - 2:00 pm EDT as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster

Rosa to present two lectures at The European Foundation of Medicinal Chemists Co …

Rosa to Present The MQM Standard and Lead Optimization Using Systems Pharmacology Modeling Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present two lectures entitled "Optimizing Lead Compound Selection Using Mechanistic Physiological Modeling" and "Qualifying Mechanistic Physiological Models for Use in Pharmaceutical Discovery and Development" on April 2, 2012, as part of the European Foundation of Medicinal Chemists

Rosa to Present Systems Pharmacology Workshop at 3rd Annual World PK/PD Summit

Rosa Workshop Presents The MQM Quality Standard For Mechanistic Modeling Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will present a pre-conference workshop entitled “Development of Mechanistic Systems Pharmacology Modeling for Insight and Decision Support” on Tuesday, 27 March 2012, as part of the 3rd Annual World PK/PD Summit, March 27 – 29, 2012 in Boston. Dr. Christina Friedrich

Rosa to Present at 2012 Keystone Symposia: Advances in Islet Biology

Modeling analysis enables development of biomarkers for beta cell mass. Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent research project will be presented at the 2012 Keystone Symposia: " Advances in Islet Biology " in Monterey, California on March 28, 2012. Dr. Mike Reed will be presenting a poster entitled "Non-invasive prediction of beta cell

Dr. Joga Gobburu to Discuss the Impact of Pharmacometrics on Drug Approvals in R …

Dr. Gobburu will present “Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions” March 20, 2012. Rosa & Co. LLC today announced that Dr. Joga Gobburu, University of Maryland, Baltimore, will present a webinar “Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions” on Tuesday, March 20, 2012 at 1:00 to 2:00 pm EST as part of Rosa’s ongoing monthly public webinar series. The purpose of the

Rosa PK/PD Collaboration with Pfizer to be Presented at ASCPT 2012

PK/PD analyses used to support the rationale for therapeutic strategies targeting myostatin pathway Rosa & Co. LLC, a drug development advisory firm with expertise in PK/PD and drug-disease modeling and simulation, today announced that results from its PK/PD collaboration with Pfizer will be presented as a poster at the 2012 American Society for Clinical Pharmacology and Therapeutics annual meeting in National Harbor, Maryland. The poster entitled "Role of Myostatin Pathway in

Rosa Announces Publication of its PhysioPD™ Model Qualification Method and Ser …

Series of Seminars and Workshops to be held in 2012 across the US and in Europe Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced the publication of its Model Qualification Method (“MQM”) in the White Paper, “Facilitating Drug Discovery and Development with Mechanistic Physiological Models that are ‘Fit for Purpose.’” Rosa created the MQM to enable the broader adoption and use

Biopontis Alliance Fund and Rosa Announce Strategic Relationship for Early Stage …

Collaboration will combine Rosa’s PhysioPD™ modeling & simulation capabilities with Biopontis’ innovative asset sourcing and financial structure to improve early drug development productivity Biopontis Alliance, Inc, (www.biopontisalliance.com) a unique firm combining early-stage capital investment with early-stage drug development, today announced that it has completed a strategic patrtnership agreement with Rosa and Co. (www.rosaandco.com), an advisory firm with leading expertise in PhysioPD and PKPD drug-disease modeling and simulation. Rosa’s capabilities will be

Dr. Hartmut Derendorf to Discuss PK/PD-based Drug Development in Rosa’s World- …

Rosa & Co. LLC today announced that Dr. Hartmut Derendorf, University of Florida, Gainesville, will present a webinar “PK/PD-based Development of Anti-infective Agents” on Monday, February 13, 2012 at 1:00 to 2:00 pm EST as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics,

Rosa to present at 2012 Keystone Symposia: Cancer and Metabolism

Modeling analysis enables understanding efficacy of large numbers of potential drug combinations. Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent research project will be presented at the 2012 Keystone Symposia: “Cancer and Metabolism” in Banff, Alberta, Canada on February 13, 2012. Dr. Christiana Friedrich will be presenting a poster entitled “Combination Therapy in Virtual NSCLC

Dr. Mike Reed to Participate in Roundtable Panel of American Society of Phamacom …

Industry presenters will focus on the Use and Benefits of Physiologic, Mechanistic Models in Drug Development Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that Mike Reed, PhD, Vice President of Client Services, will participate in a roundtable panel to discuss " The Use of Physiological, Mechanistic Models in Drug Development and Therapy: Introduction, Case Studies, Impact, and Ideas for Applications".

Pfizer and Rosa to present at 2012 Keystone Symposia: Pathogenesis of Diabetes

Insulin degradation and the mechanisms controlling it have significant impact on glucose homeostasis and diabetes. Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent collaborative research project with Pfizer will be presented at the 2012 Keystone Symposia: “Pathogenesis of Diabetes: Emerging Insights into Molecular Mechanisms” in Santa Fe, New Mexico on Monday, January 30, 2012. Dr.

Rosa’s Toufigh Gordi to Present at 2nd Annual Pediatric Pharmacology Conferenc …

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that its Dr. Toufigh Gordi, President of PKPD and Clinical Pharmacology Services, will present the results of an Accelerator Mass Spectrometry (AMS) microdosing study in infants at the 2nd Annual Pediatric Pharmacology Conference in Philadelphia, PA on January 26, 2012. Dr. Gordi will give a 30 minute scientific presentation entitled “Pediatric PK

Dr. Tristan Maurer to Discuss Translational Modeling in Support of Drug Discover …

Rosa & Co. LLC today announced that Dr. Tristan Maurer, Pfizer Inc., will present a webinar “Translational Modeling & Simulation in Support of Rational Drug Discovery: Principles, Challenges, and Examples” on Tuesday, December 13, 2011 at 1:00 to 2:00 pm EST as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster the use of Modeling

Dr. Mike Reed Joins Rosa & Co. Executive Management Team

Rosa & Co today announced that Michael Reed, Ph.D., has joined Rosa as Vice President. Dr. Reed brings deep clinical pharmacology and drug development expertise in addition to nearly 10 years of experience applying mathematical models of biologic/physiologic systems to product development issues faced by biotechnology, pharmaceutical, and consumer product companies. Before joining Rosa, Dr. Reed headed metabolic disease research at Entelos, Inc., where he supervised multiple research collaborations with

Dr. Nick Holford to Discuss the Use of Modeling in Clinical Pharmacology in Rosa …

Rosa & Co. LLC today announced that Dr. Nick Holford will present a webinar “Clinical Pharmacology = Disease Progression + Drug Action” on September 19, 2011 at 4:00 pm EDT (GMT -5:00) as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other

Rosa’s Christina Friedrich to Lead Model Qualification Workshop at ICSB 2011

The Model Qualification Method is a rigorous, systematic analysis of model relevance, uncertainty, variability, and consistency with data to ensure drug discovery/development models are “fit for purpose” Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it will be leading a workshop on its Model Qualification Method (MQM) at the 12th International Conference on Systems Biology (ICSB), the major event for

Dr. Rebecca Baillie to Describe PhysioPD™ Model Construction and Testing in Ro …

Rosa & Co. LLC today announced that Dr. Rebecca Baillie will present a webinar “How to build a PhysioPD model” on June 20, 2011 at 1:00 pm EDT (GMT -5:00) as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other life science

Rosa and FOCUS-IP Announce Strategic Alliance for Enhancing Proof-of-Concept Dru …

Rosa & Co. LLC (rosaandco.com) today announced that it has formed a strategic scientific alliance with FOCUS-IP (focus-ip.de), a leading EU-based drug development advisory firm. FOCUS-IP sources novel new drug candidates from European academic research centers and emerging biotechnology companies, leads the exploratory development of these compounds from preclinical through proof-of-concept studies, and forms early-stage strategic development partnerships with established global pharmaceutical organizations. The Rosa-FOCUS-IP alliance will strengthen FOCUS-IP’s innovative

Rosa Announces Qualification of a Novel Methodology for Prediction of Pediatric …

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced the novel results and qualification of a new Bile PhysioPD model. The model and results were presented at the 2011 American Conference on Pharmacometrics, San Diego, CA. The Bile PhysioPD model was developed to investigate bile acid metabolism and cholestasis in adult and pediatric populations. It was based entirely on literature data,

Rosa Diabetes PhysioPD™ Collaboration with Pfizer to be Presented at World PK/ …

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that results from its Diabetes PhysioPD™ collaboration with Pfizer will be presented at the Biorbis World PK/PD Summit in Cambridge, MA April 26-29, 2011. David A. Tess, Principal Scientist, of Pfizer Inc. will be presenting a 30-minute scientific presentation entitled “Creating and Using a Physiological Model to Support Development of a GPR119

Head of the US FDA Division of Pharmacometrics to Kick-off Rosa’s World-Wide W …

Rosa & Co. LLC today announced that Dr. Jogarao V. Gobburu, Head of the US FDA Division of Pharmacometrics, will present the inaugural webinar in Rosa’s monthly public webinar series “Impact of Modeling & Simulation in Drug Development” ” on April 18, 2011 at 1:00 pm EDT (GMT -5:00). The purpose of the “Impact” series is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and

Rosa Announces Six Poster Presentations at the American College on Pharmacometri …

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it has six posters scheduled during the 2011 American College on Pharmacometrics (ACoP) meeting in San Diego, CA April 3-6, 2011. The presentations describe the use of PK/PD and physiological modeling in applications from preclinical through clinical development. Five of the posters will be presented in conjunction with Lithera, MediciNova, Pfizer,

Rosa & Co. Announces the Appointment of Sharan A. Pagano as Vice President, Scie …

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced the appointment of Sharan A. Pagano, Vice President, Scientific Alliances, responsible for worldwide sales and account development, and the opening of Rosa’s new Boston, MA-area office. "I am pleased to welcome Sharan to the Rosa management team. Her unique blend of business and scientific expertise is an excellent fit for Rosa and

Rosa & Co and Vitalea Science to present at ASPCT 2011 meeting

In collaboration with Vitalea Science, Inc., Rosa & Co will present a poster at the 2011 American Society for Clinical Pharmacology and Therapeutics in Dallas, TX entitled "Compartmental Analysis of Urosodiol PK in Neonates using AMS " at 8:00 am on March 4, 2011. One of the reasons for the dearth of clinical drug testing in newborns is a lack of sensitive and non-invasive tools to support clinical trials. Most